Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: The general practice research database

International Journal of Epidemiology

Volumn 35, Issue 5, 2006, Pages 1301-1308

  de Vries, Frank ^a   de Vries, Corinne ^b   Cooper, Cyrus ^c   Leufkens, Bert ^a   van Staa, Tjeerd Pieter ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bone fractures; Case control studies; Epidemiological bias; Healthy worker effect; Hydroxymethylglutaryl CoA reductase inhibitors; Selection bias

Indexed keywords

ACIPIMOX; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BRONCHODILATING AGENT; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; METHOTREXATE; NEUROLEPTIC AGENT; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

BONE; DATA SET; DRUG PRESCRIBING; FRACTURED MEDIUM; HEALTH RISK;

AGE; AGE DISTRIBUTION; ARM FRACTURE; ARTICLE; CASE CONTROL STUDY; CLAVICLE FRACTURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; DRUG USE; EXPERIMENTAL DESIGN; FACTUAL DATABASE; FEMUR FRACTURE; FOOT FRACTURE; FRACTURE; GENDER; GENERAL PRACTICE; HAND FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; HYPERLIPIDEMIA; MALLEOLUS FRACTURE; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK ASSESSMENT; SELECTION BIAS;

EURASIA; EUROPE; UNITED KINGDOM; WESTERN EUROPE;

EID: 33750202393     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyl147     Document Type: Article

References (26)

1. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-49.
2. Meier CR, Schlienger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
3. van Staa TP, Wegman S, de Vries F et al. Use of statins and risk of fractures. JAMA 2001;285:1850-55.
4. Anonymous. Use of statins and risk of fractures - correction. JAMA 2001;286:674.
5. Meier CR, Schlienger RG, Kraenzlin ME et al. Statins and fracture risk. JAMA 2001;286:669-70.
6. Hennesy S, Strom BL. Statins and fracture risk. JAMA 2001;285:1888-89.
7. van Staa TP, Wegman S, de Vries F et al. Statins and fracture risk. JAMA 2001;286:669-70.
8. Pedersen TR, Kjekhus J. Statin drugs and the risk of fracture. JAMA 2000;284:1921-22.
9. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Lancet 2001;357:509-12.
10. Clearfield M, Downs JR, Weis S et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001;10:971-81.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
12. Hauck WW. Odds ratio inference from stratified samples. Commun Stat 1989;18A:767-800.
13. van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994;47:183-89.
14. McMahon AD, Evans JM, McGilchrist MM et al. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998;7:275-80.
15. van Beek E, Pieterman E, Cohen L et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
16. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202.
17. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
18. Ensrud KE, Barrett-Connor EL, Schwartz A et al. Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-69.
19. Bauer DC, Mundy GR, Jamal SA et al. Use of statins and fracture: Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-52.
20. Petitti D. Commentary: Hormone replacement therapy and coronary heart disease: Four lessons. Int J Epidemiol 2004;33:461-63.
21. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-79.
22. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
23. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
24. Farahmand BY, Persson PG, Michaelsson K et al. Socioeconomic status, marital status and hip fracture risk: A population-based case-control study. Osteoporosis Int 2000;11:803-08.
25. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA 2004;291:1864-70.
26. Glynn RJ, Knight EL, Levin R et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001;12:682-89.